Dan is responsible for evaluating investment opportunities, structuring new investments and monitoring portfolio companies at CI. Dan is involved with numerous boards, both as a member and an observer, and has assisted with CI’s investments in Axerion Therapeutics, AxioMx, Affinimark Technologies, CyVek, LiQuifix, Cara Therapeutics, RibX (Melinta Therapeutics), Remote Reality, Sami Health, and ShopText.
Dan contributes to CI’s expertise in biotech with more than 10 years in the industry. He was previously employed by successful former CI portfolio company CuraGen Corporation. While at CuraGen, Dan held a variety of scientific and operational management positions. His extensive experience in research and development, technology assessment and implementation of next-generation scientific technologies enabled Dan to help transform CuraGen from a genomic and proteomic platform company into a biopharmaceutical firm dedicated to advancing its protein, antibody and small-molecule therapeutics.